(UroToday.com) In this presentation, Dr. Garcia del Muro presented data from the IMMUNOPRESERVE-SOGUG trial, which aimed to test combined immunotherapy with durvalumab and tremelimumab and radiotherapy as a chemotherapy-free strategy for bladder preservation in muscle invasive bladder cancer (MIBC). The rationale for this approach is based on (1) immunotherapy has significant activity in the neoadjuvant and advanced setting for urothelial cancers and (2) the combination of radiation and dual checkpoint blockade can activate non-redundant immune mechanisms to generate anti-tumor immune activity.